TEVA-TICLOPIDINE 250 MG — DIN 02236848
TICLOPIDINE HYDROCHLORIDE : 250 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is TEVA-TICLOPIDINE?
TEVA-TICLOPIDINE 250 MG contains TICLOPIDINE HYDROCHLORIDE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02236848, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 02-May-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Ticlopidine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Ticlopidine, across 12 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 1 | 0 | TICLOPIDINE | No marketed DIN |
| ALTIMED PHARMA INC. | 1 | 0 | ALTI-TICLOPIDINE - TAB 250MG | No marketed DIN |
| APOTEX INC | 1 | 0 | TICLOPIDINE | No marketed DIN |
| DOMINION PHARMACAL | 1 | 0 | DOM-TICLOPIDINE | No marketed DIN |
| HOFFMANN-LA ROCHE LIMITED | 1 | 0 | TICLID 250MG TABLETS | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | MYLAN-TICLOPIDINE | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-TICLOPIDINE | No marketed DIN |
| PRO DOC LIMITEE | 1 | 0 | TICLOPIDINE-250 | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | SANDOZ TICLOPIDINE | No marketed DIN |
| SANIS HEALTH INC | 1 | 0 | TICLOPIDINE | No marketed DIN |
| SYNTEX INC. | 1 | 0 | TICLID TAB 250MG | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | TEVA-TICLOPIDINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Ticlopidine |
|---|---|
| ATC code | B01AC05 |
| AHFS class | 20:12.18 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02236848 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2236848 |
| Brand name | TEVA-TICLOPIDINE |
| Generic / active ingredient | TICLOPIDINE HYDROCHLORIDE : 250 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | B01AC05 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AC |
| Current status | CANCELLED POST MARKET |
| Status date | 02-May-2018 |
| Original market date | 2002-07-30 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALTI-TICLOPIDINE - TAB 250MG | 250 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 02194422 |
| DOM-TICLOPIDINE | 250 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02243808 |
| MYLAN-TICLOPIDINE | 250 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 02239744 |
| PMS-TICLOPIDINE | 250 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | 02243327 |
| SANDOZ TICLOPIDINE | 250 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02243587 |
| TICLID 250MG TABLETS | 250 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | 02162776 |
| TICLID TAB 250MG | 250 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | 01911759 |
| TICLOPIDINE | 250 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | 02343045 |
| TICLOPIDINE | 250 MG | TABLET | APOTEX INC | APPROVED | 02237560 |
| TICLOPIDINE | 250 MG | TABLET | AA PHARMA INC | DORMANT | 02237701 |
2 · Same class — other molecules in ATC B01AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Clopidogrel | ABBOTT-CLOPIDOGREL · ACCEL-CLOPIDOGREL · ACT CLOPIDOGREL · AG-CLOPIDOGREL · +22 more | 39 | 19 | Yes |
| Acetylsalicylic Acid | APO-ASA LD · ASA · ASA 81 MG · ASA DAILY LOW DOSE · +17 more | 23 | 12 | Yes |
| Ticagrelor | AG-TICAGRELOR · APO-TICAGRELOR · BRILINTA · JAMP TICAGRELOR · +3 more | 14 | 12 | Yes |
| Selexipag | UPTRAVI | 8 | 8 | Yes |
| Treprostinil | REMODULIN · TREPROSTINIL INJECTION | 8 | 4 | Yes |
| Epoprostenol | CARIPUL · EPOPROSTENOL FOR INJECTION · FLOLAN | 6 | 4 | Yes |
| Dipyridamole | APO-DIPYRIDAMOLE · APO-DIPYRIDAMOLE-SC TAB 25MG · APO-DIPYRIDAMOLE-SC TAB 50MG · APO-DIPYRIDAMOLE-SC TAB 75MG · +17 more | 24 | 2 | Yes |
| Eptifibatide | EPTIFIBATIDE INJECTION · INTEGRILIN | 14 | 2 | Yes |
| Tirofiban | AGGRASTAT | 2 | 1 | Yes |
| Prasugrel | EFFIENT · JAMP PRASUGREL | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AB | Antithrombin · Dalteparin · Danaparoid · Enoxaparin · Heparin · +3 more | 128 | 82 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-TICLOPIDINE called?
The same molecule, Ticlopidine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| THROMBOPAT | Latin | Morocco |
| TICLID | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.